Monday, July 15, 2019

Amgen Abandons Alzheimer's Prevention Study

Thousand Oaks-based Amgen, along with partners Novartis and the Banner Alzheimer's Institute, said late last week that they are discontinuing a clinical research program, which had focused on Alzheimer's prevention. According to the three, the study of BACE1 inhibitor CNP520 was discontinued, after they concluded the potential benefit for participants in the studies did not outweigh the risk. The companies said that they identified "worsening in some measures of cognitive function" during the Phase 2/3 studies. The compound had been aimed at prevention or delay of the onset of Alzheimer's disease in people at high risk for developing symptoms based on age and their genetic status.